

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A INFORMATION

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934**

(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

XERIS BIOPHARMA HOLDINGS, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee previously paid with preliminary materials.
- Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1) and 0-11.

Your vote matters!



Scan QR for digital voting

Xeris Biopharma Holdings, Inc. Annual Meeting of Stockholders

Wednesday, June 5, 2024 8:00 AM, Central Daylight Time

Annual Meeting to be held live via the internet - please visit www.proxydocs.com/XERS for more details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/XERS

For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/XERS

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 24, 2024.

SEE REVERSE FOR FULL AGENDA

Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 5, 2024 For Stockholders of record as of April 12, 2024

To order paper materials, use one of the following methods.



Internet:
www.investorelections.com/XERS



Call:
1-866-648-8133



Email:
paper@investorelections.com

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

Your control number

Have the 12 digit control number located in the box above available when you access the website and follow the instructions.



THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ON PROPOSALS 1, 2, 4 AND 5

THE BOARD RECOMMENDS THAT AN ADVISORY VOTE ON THE COMPENSATION FOR NAMED EXECUTIVE OFFICERS BE HELD EVERY 1 YEAR.

PROPOSAL

1. Election of Directors
 - 1.01 Paul R. Edick
 - 1.02 Ricki Fairley
 - 1.03 Marla S. Persky
2. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.
3. To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of our named executive officers.
4. To approve, on a non-binding advisory basis, the compensation of our named executive officers.
5. To approve an amendment to the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, to (i) remove the "evergreen" provision which provides for annual increases in the aggregate number of shares available for issuance thereunder and (ii) increase the aggregate number of shares available for issuance thereunder by 6,636,632 additional shares.

Note: To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.